Aman's Global Market Intelligence

Executive dashboard

S&P 500 · Tue close7,691.76−0.69%

Nasdaq · Tue close26,289.71−1.33%

Dow · Tue close53,343.40−0.22%

Russell 2000 · Tue3,017.89≈−1.30%

VIX · Tue close15.84+0.65 pt

U.S. 2Y / 10Y · Tue4.19% / 4.71%Long end stressed

Dollar index · 08:2299.48−0.33% vs prior ref.

WTI Sep · 08:22$84.69+3.12% vs prior ref.

Gold · 08:22$4,400.60+0.89% vs prior ref.

Nikkei · 08:1765,362≈−3.1% vs Tue close

Hang Seng · 08:1725,478near flat intraday

Shanghai · 08:173,896≈−2.4% vs Tue close

Euro Stoxx 50 · Tue6,468pre-open today

DAX / FTSE · Tue26,128 / 10,728Europe pre-open

S&P / Nasdaq futures7,707 / 29,492≈−0.1% / −0.3% vs Tue daily ref.

1 · Rates

Long-end sovereign stress

U.S. 30Y briefly reached 5.3371%, its highest in nearly 20 years, before easing toward 5.28% in Asia. German long yields hit 2011-era highs and Japan's 10Y approached 3%. Fiscal supply and inflation risk—not recession fear—are driving the repricing. Reuters

2 · Oil/geopolitics

Hormuz premium remains

Brent held above $90 with no visible progress on reopening the Strait of Hormuz; WTI was near $84.69. This creates a direct inflation/rates headwind for growth multiples and a relative tailwind for energy. Reuters

3 · Rotation

AI momentum fractures, healthcare catches bids

The SOX fell 5% Tuesday; tech lost 1.9%, while healthcare gained 1.6%, staples 1.1% and energy 1.8%. Breadth was weak, with NYSE decliners leading 1.94:1. Reuters close recap

Market drivers & session map

Macro / central banks / geopolitics

Fed minutes today, 20:00 CEST: July 28–29 meeting minutes are the day's main scheduled policy catalyst. The Fed's calendar confirms 14:00 ET publication. Federal Reserve
Debt supply: a $16bn U.S. 20-year auction adds duration supply while investors demand more term premium. Reuters
Real economy: July U.S. industrial and manufacturing production each rose 0.2% m/m; capacity use edged to 76.3%, still 3.1 points below its long-run average. Business-equipment output rose 0.8%. Fed G.17
Curve: official Aug. 18 Treasury par yields were 4.19% (2Y), 4.71% (10Y), 5.28% (30Y). U.S. Treasury

Global tape / earnings / unusual moves

Asia: MSCI Asia ex-Japan was down 1.7%; Nikkei about −2.6% at Reuters' timestamp. AP reported the KOSPI down 5.2% earlier, with Samsung −6.9% and SK Hynix −7.9%. AP
U.S. Tuesday: Nvidia −2.3%, Micron −7%; energy and defensives outperformed. Total U.S. volume of 14.86bn shares was below the 20-day 16.88bn average, so this was a sharp but not capitulation-volume selloff. Reuters
Europe: cash markets were still closed at cutoff. Latest available Tuesday closes: Euro Stoxx 50 6,468, DAX 26,128, FTSE 10,728. Reuters said European futures slipped roughly 0.1%. Yahoo quote
Rotation test: Target, Lowe's and TJX results are due Wednesday; their commentary matters for consumption and margin pressure. Reuters

Theme dashboards

AI · fragile

Semis / cloud / data centers / power

Leaders: energy/power exposure has relative support; XLE gained 1.8%. Credo's tape showed resilience in the prior dataset, but live vendor fields conflicted, so no price claim is used.
Laggards: SOX −5%; NVDA −2.3%, MU −7%, VRT −6.8% in vendor data. Rising discount rates challenge the highest-duration beneficiaries.
Primary catalyst/risk: Nvidia disclosed credit support tied to about 4.25 GW at an Ohio OpenAI campus and a cumulatively capped initial payment obligation of $105bn, with additional optional 3.8 GW support. This validates demand but introduces material contingent counterparty/lease exposure. SEC 8-K

Quantum · speculative

Useful deployment, hostile tape

Verified news: D-Wave said NTT DOCOMO deployed a second production application; in a representative 333-base-station problem, location-registration signals fell 65.3% at daily peak and paging signals 7.0%. QBTS 8-K
Tape: IONQ −5.8%, RGTI −5.1%; QTUM ETF −3.8% Tuesday in vendor data.
Risk: commercial proof points do not by themselves establish contract value, durable margins or valuation support. High rates punish distant cash flows; small-company dilution and execution risk remain central.

Peptide biotech · catalyst

Avexitide de-risks efficacy; approval remains binary

Amylyx's 78-patient randomized Phase 3 LUCIDITY trial met its FDA-agreed primary endpoint: 55% fewer composite Level 2/3 hypoglycemic events vs placebo through week 16 (p=0.000003); all secondary endpoints met. No treatment-related serious adverse events were reported; common AEs included diarrhea and injection-site reactions. Company release
AMLX closed $35.11 after the readout, about +64% versus the prior chart reference: chase risk is extreme.
Cash/investments were $250.8m at June 30; company-guided runway is into 2028. NDA submission is planned by year-end. Q2 release

Ranked ideas — fewer, higher-conviction setups

1Bullish

XLE · Energy Select Sector SPDR (NYSE Arca)

Risk class: liquid sector ETF · Classification: tactical long · Applicable horizon: day trade and 1–4 week swing; not a fresh 12-month thesis at elevated oil.

Thesis/catalyst: energy was the strongest S&P sector (+1.8%) while WTI/Brent carried a Hormuz supply premium. Relative strength should persist if WTI holds above the prior $82 area and long yields stay elevated.

Evidence / counterargument: XLE closed $63.68, +1.76%, above its 20-day average near $59.65 in vendor data. A diplomatic breakthrough or restored shipping could reverse oil violently; this is event-driven, not low-risk compounding.

Entry/confirmation: only on a hold above $63.70 after the U.S. open, or a controlled pullback that holds $62.50. Invalidation/downside: daily close below $61.80 or WTI below $81; gap risk is material. Key risks: ceasefire, demand slowdown, political intervention, commodity volatility.

Thesis Confidence 75

Risk 60

Opportunity 73

2Bullish

XBI · SPDR S&P Biotech ETF (NYSE Arca)

Risk class: diversified high-volatility biotech ETF · Classification: relative-strength long · Applicable horizon: 1–4 weeks and selective 3–12+ months.

Thesis/catalyst: healthcare gained 1.6% during tech de-risking; XBI finished around $160.11 and above a vendor-calculated 20-day mean near $153.5. Positive idiosyncratic clinical catalysts such as AMLX can support flows without single-name binary concentration.

Evidence / counterargument: rotation and trend are positive; however, higher yields still raise biotech funding costs, and policy/pricing risks can overwhelm the tape.

Entry/confirmation: hold above $159–160 or breakout above $161 on improving breadth. Invalidation/downside: close below $153.50; next risk zone roughly $150. Key risks: clinical failures, FDA surprises, dilution, reversal into mega-cap tech.

Thesis Confidence 68

Risk 64

Opportunity 66

1Avoid / bearish

IONQ · IonQ (NYSE)

Risk class: high-volatility speculative growth · Classification: avoid; bearish only on confirmation · Applicable horizon: day trade / 1–4 weeks. Direction remains uncertain above trend support.

Thesis/catalyst: IONQ fell 5.8% Tuesday to $44.12 as rates forced rotation, yet remained above its vendor-calculated 20-day mean near $39.68. That makes immediate shorting poor risk/reward; wait for structure to fail.

Evidence / counterargument: quantum basket weakness and high discount rates argue for compression. Counter: government/commercial announcements and momentum can create violent squeezes.

Entry/confirmation: bearish only on a daily break below $39.50; otherwise avoid. Invalidation/downside: bearish view invalid above $46.90; potential short loss is unlimited. No statement is made about borrow availability or fees. Risks: squeeze, contracts, M&A, low fundamental visibility.

Thesis Confidence 66

Risk 86

Opportunity 55

2Tactical avoid

NVDA · Nvidia (Nasdaq)

Risk class: mega-cap high-duration growth · Classification: avoid new tactical longs, not a structural short · Applicable horizon: day trade / 1–4 weeks only. Long-term direction uncertain.

Thesis/catalyst: $219.74 Tuesday close, −2.3%, as SOX lost 5%. Long-duration valuation is exposed to 4.7% 10Y yields, while the new 8-K adds a capped $105bn contingent-support framework tied to OpenAI leases.

Evidence / counterargument: rates and sector breadth are adverse. Counter: the 4.25 GW deployment validates enormous full-stack demand, and Nvidia's ecosystem may keep earnings momentum stronger than peers.

Entry/confirmation: do not chase downside; tactical bearish confirmation is a break below $218. Invalidation: reclaim and hold above $225, stronger above $230. Risks: earnings upside, AI capex acceleration, short squeeze; losses on shorts are unlimited.

Thesis Confidence 71

Risk 75

Opportunity 58

Watchlist — no chase orders

Ticker / class	Setup & horizon	Confirmation	Invalidation / principal risk	Scores C/R/O
Watch AMLX Nasdaq · small/mid-cap clinical biotech, binary	Positive Phase 3; 1–4 weeks / 3–12 months. Direction uncertain after ~64% gap.	Consolidation above $33 then volume-backed break over $36; prefer several sessions of price discovery.	Below $30. NDA review, endpoint interpretation, commercialization, competition, dilution. Cash runway company-guided into 2028.	82 / 88 / 72
Watch QBTS Nasdaq · speculative quantum	DOCOMO production use is concrete; 1–4 weeks only.	Hold above $20.85 then clear $21.50 on volume.	Below $19.25. Contract economics undisclosed; dilution/valuation risk.	73 / 84 / 61
Watch CRDO Nasdaq · high-growth networking	AI connectivity leader candidate; 1–4 weeks / 3–12 months.	Live vendor fields conflicted, so wait for a clean, exchange-confirmed quote and relative-strength reclaim.	No level assigned because source fields conflicted; concentration and valuation risk.	55 / 78 / 58
Watch LLY NYSE · large-cap peptide/metabolic	Higher-quality peptide exposure; 3–12+ months.	Hold above Tuesday's $1,225.73 close after broad-market stabilization.	Trial/regulatory, competition, pricing, manufacturing and rich-valuation risk.	67 / 58 / 63
Watch MU Nasdaq · cyclical memory	Potential rebound only; day trade / 1–4 weeks.	Stabilization after Tuesday's 7% fall and SOX breadth improvement.	Fresh low; AI memory expectations, cycle and valuation de-rating.	61 / 76 / 57

Changes versus previous report

Audit limitation: the injected prior-job context contains only nested/truncated job headers and no readable prior regime, levels or ranked calls. Therefore no claim-level comparison can be made without inventing history. Today's clearly new verified developments are: Tuesday's 5% SOX selloff, the Nvidia $105bn capped contingent-support disclosure, D-Wave/DOCOMO's production deployment filing, and Amylyx's positive Phase 3 readout. These are treated as new observations, not as upgrades/downgrades versus an unavailable prior call.

Important catalysts: next 7–30 days

Aug 19 · 20:00 CEST — FOMC minutes
Primary event for rate-path interpretation; watch 10Y/30Y, dollar and Nasdaq duration sensitivity. Fed calendar

Aug 19–20 — Retail earnings / China rates
Target, Lowe's, TJX and later-week Walmart commentary test consumer resilience; China is widely expected to hold benchmark lending rates. Reuters

Aug 26 · 14:30 CEST — U.S. GDP second estimate + July income/outlays
Growth/inflation combination can move the long end materially. BEA schedule

Aug 28 · 16:00 CEST — preliminary payroll benchmark
Labor-history revision can alter the soft-landing narrative. BLS

Sep 4 · 14:30 CEST — August Employment Situation
Key 16-day catalyst for Fed pricing and cyclicals. BLS

By year-end (outside 30 days) — AMLX NDA target
Not a near-term dated event, but the next major regulatory path marker; detailed LUCIDITY presentation timing remains unannounced. Amylyx

Bottom line by horizon

Day trade

Bias: defensive/risk-off until yields and oil cool. Favor XLE relative strength; avoid indiscriminate dip-buying in semis/quantum. The best reversal tell is Nasdaq holding while the 10Y/30Y stop rising.

Biggest risk: headline-driven oil reversal. Invalidation: S&P futures reclaim overnight weakness with broad semiconductor participation and falling long yields.

1–4 week swing

Bias: barbell XLE/XBI versus reduced high-duration exposure. Keep size smaller because geopolitical gaps dominate technical levels.

Biggest risk: rapid Iran/Hormuz resolution rotates leadership back to tech. Invalidation: XLE below $61.80; XBI below $153.50; 10Y sustainably back below roughly 4.60% weakens the bearish-duration thesis.

3–12+ month investment

Bias: no compelling broad-theme entry today. Build watchlists, not full positions: NVDA's demand signal is powerful but contingent exposure matters; AMLX efficacy is de-risked but approval/commercialization remain binary.

Biggest risk: paying peak multiples/commodity prices. Invalidation: durable earnings acceleration that offsets discount-rate pressure, or a material fall in oil and term premium.

Data quality & methodology

High-confidence primary data: Treasury Aug. 18 curve, Fed G.17 and calendar, SEC filings, Amylyx releases/ClinicalTrials.gov.
Market data: U.S. closes and sector moves cross-checked between Reuters and Yahoo Finance chart endpoints. Overnight futures/commodities and Asian values are indicative and can move; timestamps differ by venue.
Known limitations: Yahoo daily-history arrays omitted the final cash bar for several indices while metadata carried the correct close; Reuters was used for final S&P/Nasdaq/Dow closes. KOSPI vendor history was inconsistent, so AP's timestamped percentage is reported rather than a fabricated precise close-to-close return. CRDO vendor metadata and history conflicted, so no live level is assigned.
Europe: 08:30 CEST precedes the main cash open; Tuesday closes and pre-open futures commentary are explicitly separated.
Scores: Thesis Confidence measures evidence quality, not probability or guarantee. Risk is higher when riskier. Levels are research triggers, not automatic orders.

Aman's Global Market Intelligence — 2026-08-19